Patients can start looking forward to improved therapies for congestive heart failure, a condition for which there are widely used, inexpensive, but imperfect products - ACE inhibitors and diuretics.

The latest entrant that looks promising is Texas Biotechnology Corp.'s TBC11251 endothelin A receptor antagonist. Last week, TXB halted a double-blind Phase IIa trial of TBC11251 after the compound showed statistical significance (p<0.05) with only 8 patients in each of two TBC11251 single IV bolus dose groups and a placebo group.